Condition
Vulvar Cancer, Stage IV
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 2 (1)
Trial Status
Terminated1
Recruiting1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06639191Early Phase 1Recruiting
[177Lu]Lu-AKIR001 First-in-human Study
NCT03339765Not ApplicableCompleted
Self-Advocacy Serious Game in Advanced Cancer
NCT00003525Phase 2Terminated
Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva
Showing all 3 trials